Effect of dapagliflozin on the rate of decline in kidney function in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial.
- DOI
- 10.1016/s2213-8587(21)00242-4
- Published
- 2021 Nov
- Container
- The lancet. Diabetes & endocrinology
- Publisher
- Not recorded
- Open access
- unknown
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1016/s2213-8587-21-00242-4,
title = {Effect of dapagliflozin on the rate of decline in kidney function in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial.},
author = {Heerspink HJL and Jongs N and Chertow GM and Langkilde AM and McMurray JJV and Correa-Rotter R and Rossing P and Sjöström CD and Stefansson BV and Toto RD and Wheeler DC and Greene T and DAPA-CKD Trial Committees and Investigators},
year = {2021},
journal = {The lancet. Diabetes \& endocrinology},
doi = {10.1016/s2213-8587(21)00242-4},
url = {https://doi.org/10.1016/s2213-8587(21)00242-4}
}RIS
TY - JOUR TI - Effect of dapagliflozin on the rate of decline in kidney function in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial. AU - Heerspink HJL AU - Jongs N AU - Chertow GM AU - Langkilde AM AU - McMurray JJV AU - Correa-Rotter R AU - Rossing P AU - Sjöström CD AU - Stefansson BV AU - Toto RD AU - Wheeler DC AU - Greene T AU - DAPA-CKD Trial Committees and Investigators PY - 2021 JO - The lancet. Diabetes & endocrinology DO - 10.1016/s2213-8587(21)00242-4 UR - https://doi.org/10.1016/s2213-8587(21)00242-4 ER -
APA
HJL, H., N, J., GM, C., AM, L., JJV, M., R, C., P, R., CD, S., BV, S., RD, T., DC, W., T, G., & Investigators, D. T. C. A. (2021). Effect of dapagliflozin on the rate of decline in kidney function in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial.. The lancet. Diabetes & endocrinology. https://doi.org/10.1016/s2213-8587(21)00242-4
Source records
- pubmed · retrieved 2026-09-26T07:24:02.365Z